Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Dec 01, 2022 4:29pm
273 Views
Post# 35144428

RE:RE:CG Oncology NMIBC data

RE:RE:CG Oncology NMIBC dataThe day CGOncology will be IPOed (it's presently private via 5 Financing Series totalling so far 200M$US), we'll know exactly how much we would be worth as they are also a one indication biotech so far and are in the exact same indication (BCG-unresponsive) as us.

So with a 200M$US private equity, CG Oncology is probably valued at 2B$US.

The advantage we have, is that we are in TLT @0.30$ on average.  Once CG Oncology will be IPOed, their stock will probably start trading around 10$-15$US or around 1-2B$US in market valuation.  So we already have a huge 20-30-45x advantage in being already in TLT.  And we have whiners here!!! lollll

We just need to be patient again, for a few months, in the early months of 2023.  
<< Previous
Bullboard Posts
Next >>